Oxford Centre for Diabetes, Endocrinology and Metabolism

OCDEM is a pioneering centre that combines clinical care, research and education in diabetes, endocrine and metabolic diseases. By promoting world-class research, we aim to enhance understanding of these diseases and to accelerate the search for new treatments and cures.

Head of OCDEM

David Ray

Professor of Endocrinology, Head of OCDEM, and Co-Director Sir Jules Thorn Sleep and Circadian Neuroscience Institute

david.ray@ocdem.ox.ac.uk

History

Read about the beginnings of our centre.

Find out more

Latest publications

Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Golubic R. et al, (2024), Diabet Med
Bidirectional Mendelian Randomization Highlights Causal Relationships Between Circulating INHBC and Multiple Cardiometabolic Diseases and Traits.
Loh NY. et al, (2024), Diabetes, 73, 2084 - 2094
Enhancing postpartum cardiometabolic health for women with previous gestational diabetes: Next steps and unanswered questions for pharmacological and lifestyle strategies
Golubic R. et al, (2024), Diabetes, Obesity and Metabolism
Abstract 4144972: Predictors of cardiovascular disease risk and total mortality: Findings from the UK Biobank.
Agwara EO. et al, (2024), Circulation, 150

Two researchers in lab coats By promoting world-class research, we aim to enhance understanding of diseases and to accelerate the search for new treatments and cures. We are one of the largest dedicated research centres in diabetes, endocrinology and metabolism in Europe, hosting a large number of world-leading scientists and a total of about 110 academic staff. Led by Prof Fredrik Karpe, work in OCDEM spans the spectrum of basic, translational and on to patient-orientated research. We are closely integrated with excellent clinical care for patients with diabetes, metabolic and endocrine conditions.

Our particular areas of strength are:

Type 2 diabetes including genomics, islet biology and function, novel therapeutics and large-scale clinical trials providing evidence for best practise
Human integrative metabolic physiology
Endocrine disorders such as glucocorticoid action, pituitary tumours and calcium homeostasis

Our major funders include AstraZeneca, the European Commission, the Medical Research Council, Merck & Co and the Wellcome Trust.